NEW DELHI (Reuters) – Pfizer Inc has applied for emergency use authorisation of its coronavirus vaccine in India, a top government health adviser said in a TV interview on Sunday, the first to do so in a country with the world’s second-highest number of infections.
The U.S. company, whose vaccine was recently approved in Britain, approached Indian authorities on Saturday, V.K. Paul, who is advising the government on COVID-19 matters, said.
“We welcome interest from Pfizer to seek emergency licensure in our country,” Paul told NDTV.
India’s drugs regulator typically takes up to 90 days to decide on such applications but a decision on Pfizer’s vaccine could come much faster than that, Paul said.